Radiotherapy of gynaecological cancers in the light of the report of the ESTRO 37 conference
PDF (Język Polski)


endometrial cancer
cervical cancer
gynaecological brachytherapy
postoperative radiotherapy

How to Cite

Płachta, M. (2019). Radiotherapy of gynaecological cancers in the light of the report of the ESTRO 37 conference. Letters in Oncology Science, 16(3), 23-26.


The aim of this paper is to present  the most important trends of radiotherapy of gynaecological cancers, presented during the 37th conference of European SocieTy for Radiotherapy and Oncology (ESTRO) in Barcelona in 2018.
PDF (Język Polski)


Wojciechowska U, Didkowska J. Zachorowania i zgony na nowotwory złośliwe w Polsce. Krajowy Rejestr Nowotworów, Centrum Onkologii - Instytut im. Marii Skłodowskiej - Curie. Dostępne na stronie dostęp z dnia 15/03/2019.

Kornafel J, Mądry R. Nowotwory kobiecego układu płciowego. Zalecenia postępowania diagnostyczno-terapeutycznego w nowotworach złośliwych. Via Medica, Gdańsk 2013: 265–317.

Bertelsen K, Ortoft G, Hansen ES. Survival of Danish patients with endometrial cancer in the intermediate-risk group not given postoperative radiotherapy: the Danish Endometrial Cancer Study (DEMCA). Int J Gynecol Cancer 2011;21(7):1191-9. DOI:

Poulsen HK. The Danish Endometrial Cancer Study (DEMCA). Acta Oncol 1989;28(4):589-93. DOI:

G. Ortoft. Symposium: Do we need adjuvant vaginal BT in endometrial cancer? No, not necessary, the Danish experience. Materiały zjazdowe ESTRO 37, Turyn 2018.

Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Wárlám-Rodenhuis CC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 2000;355(9213):1404-11. DOI:

Creutzberg CL, Nout RA, Lybeert ML, Wárlám-Rodenhuis CC, Jobsen JJ, Mens JW, et al. Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma. Int J Radiat Oncol Biol Phys 2011;81(4):e631-8. DOI:

Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004;92(3):744-51. DOI:

Stahl JM, Damast S, Bledsoe TJ, An Y, Verma V, Yu JB, et al. Cost-effectiveness of adjuvant intravaginal brachytherapy in high-intermediate risk endometrial carcinoma. Brachytherapy 2018;17(2):399-406. DOI:

Harkenrider MM, Adams W, Block AM, Kliethermes S, Small W Jr, Grover S. Improved overall survival with adjuvant radiotherapy for high-intermediate and high risk Stage I endometrial cancer. Radiother Oncol 2017;122(3):452-457. DOI:

Rydzewski NR, Strohl AE, Donnelly ED, Kanis MJ, Lurain JR, Nieves-Neira W , et al. Receipt of vaginal brachytherapy is associated with improved survival in women with stage I endometrioid adenocarcinoma of the uterus: A National Cancer Data Base study. Cancer 2016;122(23):3724-3731. DOI:

Lee CM, Szabo A, Shrieve DC, Macdonald OK, Gaffney DK. Frequency and effect of adjuvant radiation therapy among women with stage I endometrial adenocarcinoma. JAMA 2006;295(4):389-97. DOI:

Cibula D, Pötter R, Planchamp F, Avall-Lundqvist E, Fischerova D, Haie Meder C , et al. The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients With Cervical Cancer. Int J Gynecol Cancer 2018;28(4):641-655. DOI:

Creative Commons License

This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.


Download data is not yet available.